Business
Ondine starts first UK health economics study
Ondine starts first UK health economics study.
About this update from Ondine Biomedical, Inc.
[{"type":"text","content":"\n\nONDINE BIOMEDICAL INC.\n(\"Ondine Biomedical\", \"Ondine\", or the \"Company\")\nOndine starts first UK health economics study\nThe York Health Economic Consortium will undertake the first UK health economic analysis of Ondine's Steriwave light-activated antimicrobial to reduce Surgical Site Infections\nOndine Biomedical Inc. (LON:OBI), Mid Yorkshire Teaching NHS Trust, and Health Innovation Yorkshire and Humber are partnering with the York Health Economics Consortium (YHEC) to evaluate the use of Ondine's light-activated antimicrobial, Steriwave®, to reduce the incidence of surgical site infections (SSIs).\nSSIs are one of the most common healthcare-associated infections (HAIs) and affect one in every 20 patients who undergo a surgical procedure in the NHS. SSIs can cost up to £100,000 per patient, and the overall cost of HAIs to NHS England is over £2 billion a year. These costs are expected to rise as growing rates of antimicrobial resistance (AMR) make the current standard of care - the antibiotic mupirocin - less effective.\n \nSteriwave uses a proprietary photosensitizer, which is activated by a specific wavelength of red light, to eliminate infection-causing pathogens in the nose. The nose is a reservoir for pathogens like Staphylococcus aureus and MRSA which are known to cause SSIs. Steriwave eliminates these pathogens, including superbugs, in a painless five-minute treatment and prevents them from spreading and causing infections. Importantly, unlike today's antibiotics, the use of Steriwave does not trigger antimicrobial resistance.\n\nThe health economic analysis is being undertaken by YHEC, an internationally renowned provider of health economics evaluations, and will supplement the ongoing Steriwave pilot at Mid Yorkshire Teaching NHS Trust, which involves 500 elective hip and knee surgery patients over a period of six months. The findings will be used to support adoption of Steriwave across the NHS.\nDr Stuart Bond, Consultant Antimicrobial Pharmacist and Director of Innovation at Mid Yorkshire Teaching NHS Trust, commented: \"We are very pleased to be partnering with Ondine and the YHEC on this economic analysis to support the promising results of the Steriwave pilot we have seen so far. The data from the health economic analysis will support the results of our pilot, and we hope to be able to share...